|
|
| Line 1: |
Line 1: |
| | | | |
| | ==Crystal structure of HsaD bound to 3,5-dichloro-4-hydroxybenzenesulphonic acid== | | ==Crystal structure of HsaD bound to 3,5-dichloro-4-hydroxybenzenesulphonic acid== |
| - | <StructureSection load='5jz9' size='340' side='right' caption='[[5jz9]], [[Resolution|resolution]] 2.68Å' scene=''> | + | <StructureSection load='5jz9' size='340' side='right'caption='[[5jz9]], [[Resolution|resolution]] 2.68Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[5jz9]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Mycto Mycto]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5JZ9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5JZ9 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[5jz9]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Mycobacterium_tuberculosis_CDC1551 Mycobacterium tuberculosis CDC1551]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5JZ9 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5JZ9 FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=6OR:3,5-DICHLORO-4-HYDROXYBENZENE-1-SULFONIC+ACID'>6OR</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.68Å</td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2vf2|2vf2]]</td></tr>
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=6OR:3,5-DICHLORO-4-HYDROXYBENZENE-1-SULFONIC+ACID'>6OR</scene></td></tr> |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">hsaD, bphD, MT3674 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=83331 MYCTO])</td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5jz9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5jz9 OCA], [https://pdbe.org/5jz9 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5jz9 RCSB], [https://www.ebi.ac.uk/pdbsum/5jz9 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5jz9 ProSAT]</span></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5jz9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5jz9 OCA], [http://pdbe.org/5jz9 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5jz9 RCSB], [http://www.ebi.ac.uk/pdbsum/5jz9 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5jz9 ProSAT]</span></td></tr> | + | |
| | </table> | | </table> |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/HSAD_MYCTO HSAD_MYCTO]] Catalyzes the hydrolysis of a carbon-carbon bond in 4,5: 9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate (4,9-DSHA) to yield 9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oate (DOHNAA) and 2-hydroxy-hexa-2,4-dienoate (HHD). Is also able to catalyze the hydrolysis of 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid (HOPDA) and the synthetic analog 8-(2-chlorophenyl)-2-hydroxy-5-methyl-6-oxoocta-2,4-dienoic acid (HOPODA) (By similarity). | + | [https://www.uniprot.org/uniprot/HSAD_MYCTU HSAD_MYCTU] Catalyzes the hydrolysis of a carbon-carbon bond in 4,5: 9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate (4,9-DSHA) to yield 9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oate (DOHNAA) and 2-hydroxy-hexa-2,4-dienoate (HHD). Is also able to catalyze the hydrolysis of 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid (HOPDA) and the synthetic analog 8-(2-chlorophenyl)-2-hydroxy-5-methyl-6-oxoocta-2,4-dienoic acid (HOPODA).<ref>PMID:19875455</ref> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 24: |
Line 23: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Mycto]] | + | [[Category: Large Structures]] |
| - | [[Category: Abihammad, A]] | + | [[Category: Mycobacterium tuberculosis CDC1551]] |
| - | [[Category: Ballet, R]] | + | [[Category: Abihammad A]] |
| - | [[Category: Bhakta, S]] | + | [[Category: Ballet R]] |
| - | [[Category: Ciulli, A]] | + | [[Category: Bhakta S]] |
| - | [[Category: Eleftheriadou, O]] | + | [[Category: Ciulli A]] |
| - | [[Category: Evangelopoulos, D]] | + | [[Category: Eleftheriadou O]] |
| - | [[Category: Halman, A]] | + | [[Category: Evangelopoulos D]] |
| - | [[Category: Keany, S]] | + | [[Category: Halman A]] |
| - | [[Category: Lack, N A]] | + | [[Category: Keany S]] |
| - | [[Category: Lowe, E]] | + | [[Category: Lack NA]] |
| - | [[Category: McHugh, T D]] | + | [[Category: Lowe E]] |
| - | [[Category: Polycarpou, E]] | + | [[Category: McHugh TD]] |
| - | [[Category: Ryan, A]] | + | [[Category: Polycarpou E]] |
| - | [[Category: Sieg, C]] | + | [[Category: Ryan A]] |
| - | [[Category: Sim, E]] | + | [[Category: Sieg C]] |
| - | [[Category: Sinclair, A]] | + | [[Category: Sim E]] |
| - | [[Category: Cholesterol]]
| + | [[Category: Sinclair A]] |
| - | [[Category: Hsad]]
| + | |
| - | [[Category: Hydrolase]]
| + | |
| - | [[Category: Inhibitor]]
| + | |
| - | [[Category: M. tuberculosis]]
| + | |
| - | [[Category: Mcp-hydrolase]]
| + | |
| Structural highlights
Function
HSAD_MYCTU Catalyzes the hydrolysis of a carbon-carbon bond in 4,5: 9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate (4,9-DSHA) to yield 9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oate (DOHNAA) and 2-hydroxy-hexa-2,4-dienoate (HHD). Is also able to catalyze the hydrolysis of 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid (HOPDA) and the synthetic analog 8-(2-chlorophenyl)-2-hydroxy-5-methyl-6-oxoocta-2,4-dienoic acid (HOPODA).[1]
Publication Abstract from PubMed
BACKGROUND AND PURPOSE: With the emergence of extensively drug-resistant tuberculosis there is a need for new anti-tubercular drugs that work through novel mechanisms of action. The meta cleavage product hydrolase, HsaD, has been demonstrated to be critical to the survival of Mycobacterium tuberculosis in macrophages and is encoded in an operon involved in cholesterol catabolism, which is identical in M. tuberculosis and M. bovis BCG. EXPERIMENTAL APPROACH: We generated a mutant strain of M. bovis BCG with a deletion of hsaD and tested its growth on cholesterol. Using a fragment based approach, over 1,000 compounds were screened by a combination of differential scanning fluorimetry, NMR spectroscopy and enzymatic assay with pure recombinant HsaD to identify potential inhibitors. We used enzymological and structural studies to investigate derivatives of inhibitors identified and to test their effects on growth of M. bovis BCG and M. tuberculosis. KEY RESULTS: The hsaD deleted strain is unable to grow on cholesterol as sole carbon source but can grow on glucose. Of seven chemically distinct "hits" from the library, two chemical classes of fragments were found to bind in the vicinity of the active siteof HsaD by X-ray crystallography. The compounds also inhibited growth of M. tuberculosis on cholesterol. The most potent inhibitor of HsaD was found also to be the best inhibitor of mycobacterial growth on cholesterol-supplemented minimal medium. CONCLUSIONS AND IMPLICATIONS: We propose that HsaD is a novel therapeutic target which should be fully exploited in order to design and discover new anti-tubercular drugs.
Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approach.,Ryan A, Polycarpou E, Lack NA, Evangelopoulos D, Sieg C, Halman A, Bhakta S, Eleftheriadou O, McHugh TD, Keany S, Lowe ED, Ballet R, Abuhammad A, Jacobs WR Jr, Ciulli A, Sim E Br J Pharmacol. 2017 Apr 5. doi: 10.1111/bph.13810. PMID:28380256[2]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Lack NA, Yam KC, Lowe ED, Horsman GP, Owen RL, Sim E, Eltis LD. Characterization of a carbon-carbon hydrolase from Mycobacterium tuberculosis involved in cholesterol metabolism. J Biol Chem. 2010 Jan 1;285(1):434-43. Epub 2009 Oct 29. PMID:19875455 doi:10.1074/jbc.M109.058081
- ↑ Ryan A, Polycarpou E, Lack NA, Evangelopoulos D, Sieg C, Halman A, Bhakta S, Eleftheriadou O, McHugh TD, Keany S, Lowe ED, Ballet R, Abuhammad A, Jacobs WR Jr, Ciulli A, Sim E. Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approach. Br J Pharmacol. 2017 Apr 5. doi: 10.1111/bph.13810. PMID:28380256 doi:http://dx.doi.org/10.1111/bph.13810
|
